Biomedical start-up Epilog, a spin-off company of Ghent University and imec, also becomes a spin-off of UAntwerp. Both partners have plenty of ambition: their aim is to develop predictive biomarkers for Alzheimer's disease in the short term rather than the long term, enabling doctors to diagnose the disease much more quickly.
newsroom
License agreement with University of Antwerp creates opportunities in fight against Alzheimer's
